Jingjing Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingjing Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Jinghang Zhang
Department of Pathology The First Affiliated Hospital of Xinxiang Medical University Weihui China
2 shared publicationsKelei Zhao
Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China
2 shared publications- Ping Lu
Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China
2 shared publications Xiaohan Yuan
Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China
2 shared publicationsMin Zhang
Department of Oncology The First Affiliated Hospital of Xinxiang Medical University Weihui China
1 shared publication- Min Zhang
Department of Oncology, The First Affiliated Hospital of Henan Medical University, Xinxiang, China
1 shared publication
Latest Publications
- Open Access
- 22 June 2025
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 19 (6) , e70081
Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP‐Endostar Combination Therapy
This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow‐up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).
- 22 June 2025
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 19 (6) , e70081
Open AccessPatient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP‐Endostar Combination Therapy
This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow‐up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).
- Open Access
- 8 December 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (12) , e70036
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.
- 8 December 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (12) , e70036
Open AccessRapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
SMARCA4‐deficient undifferentiated tumor (SMARCA4‐UT) in the chest is a high‐grade malignant tumor that grows rapidly and often carries a poor prognosis. Unfortunately, there are currently no effective treatment available until now. Here, we report a case of SMARCA4‐UT in a patient who showed a swift response to a combination treatment of penpulimab, anlotinib, and chemotherapy. A 55‐year‐old man was diagnosed with thoracic SMARCA4‐UT along with metastases to multiple lymph nodes, the pleura, and bones. Immunohistochemical (IHC) testing indicated the absence of PD‐L1 expression in tumor cells. He was given sintilimab and anlotinib as first line treatment. However, a follow‐up chest CT revealed progressive disease (PD) after the first cycle treatment. Subsequently, the second line regimen was modified to etoposide and cisplatin (EP) combined with anlotinib and penpulimab. The effectiveness evaluation revealed partial remission (PR) following two cycles of the second‐line regimen treatment. Notably, the patient's progress‐free survival (PFS) exceeds 7 months and the overall survival up to 12 months. Our case implies that a combination of chemotherapy, anlotinib, and penpulimab might offer a promising therapeutic approach for PD‐L1‐negative thoracic SMARCA4‐UT.